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STATEMENT OF TRANSLATIONAL RELEVANCE
Expression of membrane B7-H1 immune inhibitory molecules by clear cell renal cell carcinoma (ccRCC) tumors is associated with poor patient outcome.
Mechanisms by which membrane B7-H1-positive tumors cells, detected immunohistochemically, thwart anti-tumoral responses are largely conjectural.
Using a B7-H1-specific ELISA we determined that higher preoperative levels of circulating soluble B7-H1 (sB7-H1) molecules in ccRCC patients were associated with aggressive pathologic features and an increased risk of death. Release of sB7-H1 molecules may be a tumor mechanism for impairing anti-tumoral responses systemically. Treatments to inactivate or remove serum sB7-H1 molecules may be clinically beneficial.
INTRODUCTION
Considerable uncertainty exists regarding the existence and molecular forms of circulating coregulatory molecules.
Soluble forms of B7-family coregulatory proteins (including B7.1, B7.2, CD28, CTLA-4, and B7-H4) in sera of patients with malignancy, infection and autoimmune disorders have been claimed to be detected (1) (2) (3) (4) (5) , invariably without accompanying biochemical proof.
Whether soluble B7-H1 (sB7-H1) exists, too, remains an unresolved issue.
Conflicting B7-H1 serological studies have led to a misperception that the existence of sB7-H1 is firmly established (6) (7) (8) . Wan et al suggested that sB7-H1
is present and elevated among rheumatoid arthritis patients. However, those results, largely obtained with potentially cross-reacting polyclonal antibodies, were questioned (7) and not confirmed (8) .
Prompted by these contradictory reports, and because membrane expression of B7-H1 among a small percentage of tumor cells in patients with clear cell renal cell carcinoma (ccRCC) affords a dismal prognosis (9, 10), we developed a sB7-H1 ELISA and biochemically confirmed the identity of the detected protein. We then measured levels of sB7-H1 in ccRCC patient and normal control sera and correlated sB7-H1 levels with pathologic features of ccRCC tumors and patient outcome.
MATERIALS AND METHODS

Development of antibodies against B7-H1.
The detection antibody, 5H1-A3, was subcloned from the anti-B7-H1 producing 5H1 hybridoma (11) . To generate the capture antibody, 2.2B, 624MEL cells were transfected with fulllength human B7-H1 (11) and injected (5x10 6 cells/injection) intraperitoneally into Balb/c mice weekly for 6 weeks. Immune splenocytes were isolated and fused with A38 cells to form a hybridoma using standard techniques (12) . 5H1-A3 and 2.2B hybridoma supernatants were screened by ELISA for reactivity against a recombinant human protein B7-H1-human IgG (R&D Systems) which only contains the extracellular domain of B7-H1 (amino acids 19 to 239) and for absence of cross-reactivity to an irrelevant recombinant protein P-Selectinhuman IgG (BD Biosciences) or mouse immunoglobulins (Sigma). Figures S1B and S1C) . The configuration of 2.2B (capture) and 5H1-A3 (detection) exhibits an optimal detection range (C 2.5 to C 97.5 ) between 0.086 and 3.67 ng/mL, with a coefficient of variation of PD-1, all from R&D Systems), immunoglobulin or third party recombinant protein (P-selectin, R&D Systems) expressing a shared Fc carrier element ( Figure 1A) .
Binding of 2.2.B or 5H1-A3 to B7-H1 in the ELISA can be blocked by preincubating appropriate standards with antibody (data not shown).
2.2B was used as the plate-fixed capture antibody and biotinylated 5H1-A3 was used as the detection antibody. Biotinylation was performed using a solid-phase kit (Pierce). Individual ELISA steps involved three washes using a TBS + 0.05% Tween-20 buffer. High-binding polystyrene plates (Corning Life Sciences) were coated for 2h at 21°C with 0.2µg/well of 2.2B. Free binding sites were blocked with 200µL/well of Superblock (Pierce) 1h at 21°C. After washing, 50µL of sample were added to 50 µL of assay buffer (PBS + 1% BSA) and incubated overnight at 4°C. Biotinylated 5H1-A3 (100µL/well at 1µg/mL diluted in PBS + 0.1% BSA) was added and incubated 1h at 21°C. 100µL/well of horseradish peroxidase-conjugated streptavidin (BD Biosciences) diluted in PBS + 0.1% BSA was added and incubated 1h at 21°C. Plates were developed with TMB (Pierce), stopped using 0.5N H 2 SO 4 and read at 450nm using a Benchmark
Plus plate reader and associated software (Bio-Rad). For calibration, each plate was loaded with parallel dilutions of recombinant B7-H1 fusion protein (R&D Systems) ranging in concentration from 0.07 -10 ng/mL.
Calibration of the B7-H1 ELISA against standard B7-H1 dilution curves was done by fitting a 4-parameter logistic regression model using the drc package for R (13, 14) . A calibration plot with 95% confidence and prediction intervals was generated using 16 consecutive and independent assays using supernates were passed through a 2.2B affinity column coupled to a BioLogic LP monitor (Bio-Rad). Following sB7-H1 capture, the column was thoroughly washed and 1mL fractions eluted with 0.1M glycine buffer pH 2.7. Collected fractions were tested by ELISA to identify sB7-H1-positive containing samples.
Positive fractions were treated with cold acetone to precipitate sB7-H1 protein.
Pellets were resuspended in reducing buffer, boiled at 95°C x 10 min and loaded onto duplicate polyacrylamide gels. Proteins from one gel were transferred to a PDVF membrane and blotted with 5H1-A3-biotin to localize sB7-H1 bands. The second gel was fixed, and proteins revealed by silver staining (17) . B7-H1-positive bands from immunoblotting and silver gel staining were aligned and excised. The sB7-H1 material was digested in situ with trypsin and prepared for mass spectrometry analysis (18) . Protein identification was performed by nanoflow liquid chromatography electrospray tandem mass spectrometry (nanoLC-ESI-MS/MS) using a LTQ Orbitrap Hybrid Mass Spectrometer (ThermoElectron Bremen) coupled to a nanoLC-2D HPLC system (Eksigent). Peptide sequences were analyzed against the Swissprot database. Confirmation of protein identity as B7-H1 was based on a >95% probability of sequence alignment for a minimum of three peptides.
Apoptosis assay for activated human T cells. Normal human PBMCs
were isolated from leukoreduction filters (Pall) as previously described (19, 20) . above, 172 consented to provide preoperative blood samples for our biospecimen repository and had archived sera available for study. There was not a statistically significant difference in overall survival between patients who did and did not consent to provide blood samples (p=0.38; log-rank test). Serum samples were stored at -80°C until used.
To perform the B7-H1 ELISA, serum samples were thawed at 4°C and tested in duplicate along with protein standards and controls. The technician performing the B7-H1 ELISA was blinded to the pathologic features and outcome of the ccRCC patients analyzed. Associations of the average of the duplicate sB7-H1 levels with clinical and pathologic features of the ccRCC patients were evaluated using Spearman rank correlation coefficients and Kruskal-Wallis and Wilcoxon rank sum tests. Associations of sB7-H1 levels with patient outcome following surgery were evaluated using Cox proportional hazards regression models, both univariately and after adjusting for the Stage, Size, Grade, and Necrosis (SSIGN) score (23) developed specifically for patients with ccRCC. For these analyses, sB7-H1 levels were transformed to the log(2) scale so that they were approximately normally distributed. Sera from the normal controls were obtained from healthy volunteers undergoing blood donation at the Mayo Clinic Department of Transfusion Medicine. sB7-H1 levels in these 100 specimens (50 ccRCC patients and 50 normal controls) were again tested in duplicate in two consecutive experiments. sB7-H1 levels were compared between ccRCC patients and normal controls univariately and after adjusting for age and gender using a Wilcoxon rank sum test and a linear model of the log(2) transformed sB7-H1. The intra-and inter-assay reproducibility of the B7-H1 ELISA were assessed using Lin's concordance correlation coefficient cause was 1.41 (95% CI 1.08-1.83; p=0.010), indicating that a doubling of sB7-H1 was associated with a 41% increase in the risk of death. The hazard ratio for the association of log(2) sB7-H1 with death after adjusting for the SSIGN score was 1.29 (95% CI 0.95-1.76; p=0.11).
RESULTS
ELISA measurement of sB7-H1 in
sB7-H1 in normal controls and ELISA reproducibility. sB7-H1 levels were significantly elevated for the 50 randomly selected ccRCC cases compared with normal controls (p<0.001), even after adjusting for age and gender (p=0.016). These results warrant further investigation. In this cohort, 8 patients (5%)
were treated preoperatively for metastatic disease, which was not sufficient to evaluate the influence of various systemic treatments on preoperative sB7-H1 levels. Although we identified elevated preoperative sB7-H1 levels among patients with more aggressive tumors, it is not known if sB7-H1 levels fluctuate during tumor progression or remission. Likewise, although we determined that sB7-H1 levels in ccRCC patients were significantly higher than in normal controls, this study was not designed to establish sB7-H1 as screening tool.
Rather, the goal of this study was to investigate associations of preoperative sB7-H1 levels with pathologic features and patient outcome for patients with confirmed ccRCC.
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